Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial

BACKGROUND: Several countries have implemented a 2-dose (2D) human papillomavirus (HPV) vaccination schedule for adolescents based on immunobridging studies. We compared immunogenicity of 2D vs 3-dose (3D) schedules of the quadrivalent vaccine (4vHPV) up to 10 years after the first dose. METHODS: Gi...

Descripción completa

Detalles Bibliográficos
Autores principales: Donken, Robine, Dobson, Simon R M, Marty, Kim D, Cook, Darrel, Sauvageau, Chantal, Gilca, Vladimir, Dionne, Marc, McNeil, Shelly, Krajden, Mel, Money, Deborah, Kellner, James, Scheifele, David W, Kollmann, Tobias, Bettinger, Julie A, Liu, Shuzhen, Singer, Joel, Naus, Monika, Sadarangani, Manish, Ogilvie, Gina S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428395/
https://www.ncbi.nlm.nih.gov/pubmed/31617568
http://dx.doi.org/10.1093/cid/ciz887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428395/
https://www.ncbi.nlm.nih.gov/pubmed/31617568
http://dx.doi.org/10.1093/cid/ciz887

Ejemplares similares